Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 2,006 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Major Depression
Interventions: L-leucine, L-lysine; Drug
Lead sponsor: Emory University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obstructive Sleep Apnea Syndrome
Interventions: Sleep Study, Neurocognitive Testing, CBF During Wakefulness, CBF During Sleep; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 12 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gingival Recession
Interventions: Coronally Advanced Flap, Intrasulcular Tunneling, Vestibular Incision Subperiosteal Tunnel Access (VISTA), Leukocyte-Platelet Rich Fibrin (L-PRF); Procedure · Biological · Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer, Adjustment Disorders
Interventions: MDMA; Drug
Lead sponsor: Sunstone Medical; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bowel Preparation
Interventions: CLENPIQ, MIRALAX, SENNA; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 12 Months to 8 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Mobile, Alabama • San Diego, California • Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Conditions: Neuroma
Interventions: Regenerative Peripheral Nerve Interface (RPNI) surgery, Traction Neurectomy; Procedure
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Cognitive Impairment, Creativity
Interventions: Musical arts intervention; Behavioral
Lead sponsor: William Marsh Rice University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cocaine Use Disorder
Interventions: Money, Cocaine HCl; Behavioral · Drug
Lead sponsor: Joshua A. Lile, Ph.D.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Fibromyalgia
Interventions: Guided Imagery; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions: XEN496, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Orange, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Substance Abuse, Suicide, Depression
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), sham rTMS; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy, Physical Activity
Interventions: Control, Aerobic Exercise; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 20 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Aging, Knowledge, Attitudes, Practice, Long-Term Care, Dementia
Interventions: essentiALZ, Project ECHO; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 1,764 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose; Biological
Lead sponsor: Ichnos Sciences SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more

Conditions: Healthy
Interventions: Sham transcranial magnetic stimulation (TMS), Real transcranial magnetic stimulation (TMS); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Synaquell(TM), Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 1
Interventions: Regular pasta, High protein pasta, White rice; Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Obesity, Critical Illness
Interventions: Imipenem/Cilastatin/Relebactam 1.25g; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Aging, Cognitive Benefits, Cardio Respiratory Fitness, Brain Activity
Interventions: High-Intensity Interval Training; Behavioral
Lead sponsor: Colby-Sawyer College; Other
Eligibility: 55 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New London, New Hampshire

Search by objective public record fields.

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

Leucine in Midlife Depression

Cerebral Blood Flow and Childhood Obstructive Sleep Apnea

Efficacy of Methods to Treat Multiple Gingival Recession Defects

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Platelet Rich Plasma Injections In Young And Old Human Subjects

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation

Cognitive Health Research on Musical Arts

Neurobehavioral Mechanisms of Cocaine Choice

Study to Explore the Relationships Among Immunity and Stress and the Symptoms of Fatigue, Pain, and Mood Following Guided Imagery in Women With Fibromyalgia

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Functional Connectivity Alterations in Suicidal Patients Among Opioid Users

Cerebrovascular Response to Acute Exercise

Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Testing the Contribution of Orbitofrontal Cortex Networks to Reward Identity Learning

The Effect of Synaquell™ in Contact Sport Athletes

A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Cardiorespiratory Fitness and Acute High-Intensity Exercise Effects on Brain and Cognitive Function in Older Adults